Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

PET studies in dementia.

Herholz K.

Ann Nucl Med. 2003 Apr;17(2):79-89. Review.

PMID:
12790355
2.

Positron emission tomography imaging in dementia.

Herholz K, Carter SF, Jones M.

Br J Radiol. 2007 Dec;80 Spec No 2:S160-7. doi: 10.1259/bjr/97295129. Review.

PMID:
18445746
3.

Clinical application of positron emission tomography for diagnosis of dementia.

Ishii K.

Ann Nucl Med. 2002 Dec;16(8):515-25. Review.

PMID:
12593416
4.

Brain fluorodeoxyglucose (FDG) PET in dementia.

Kato T, Inui Y, Nakamura A, Ito K.

Ageing Res Rev. 2016 Sep;30:73-84. doi: 10.1016/j.arr.2016.02.003. Epub 2016 Feb 11. Review.

PMID:
26876244
5.

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

Herholz K.

Expert Rev Neurother. 2010 Nov;10(11):1667-73. doi: 10.1586/ern.10.136. Review.

PMID:
20977325
6.
8.

Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia.

Mielke R, Heiss WD.

J Neural Transm Suppl. 1998;53:237-50. Review.

PMID:
9700661
9.

FDG PET and differential diagnosis of dementia.

Herholz K.

Alzheimer Dis Assoc Disord. 1995 Spring;9(1):6-16. Review.

PMID:
7605624
10.

Guidance for reading FDG PET scans in dementia patients.

Herholz K.

Q J Nucl Med Mol Imaging. 2014 Dec;58(4):332-43. Epub 2014 Nov 13. Review.

11.

Positron emission tomography in dementia.

Santens P, Petit H.

Acta Neurol Belg. 1997 Sep;97(3):192-5. Review.

PMID:
9345592
12.

Positron emission tomography in the differential diagnosis of organic dementias.

Heiss WD, Kessler J, Szelies B, Grond M, Fink G, Herholz K.

J Neural Transm Suppl. 1991;33:13-9. Review.

PMID:
1753242
13.

Positron emission tomography findings in dementia disorders: contributions to differential diagnosis and objectivizing of therapeutic effects.

Heiss WD, Herholz K, Pawlik G, Hebold I, Klinkhammer P, Szelies B.

Keio J Med. 1989 Jun;38(2):111-35. Review.

14.

Positron emission tomography imaging of regional cerebral glucose metabolism.

Alavi A, Dann R, Chawluk J, Alavi J, Kushner M, Reivich M.

Semin Nucl Med. 1986 Jan;16(1):2-34. Review.

PMID:
2935938
15.

Emission tomography in dementia.

Pakrasi S, O'Brien JT.

Nucl Med Commun. 2005 Mar;26(3):189-96. Review.

PMID:
15722899
16.

FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?

Mosconi L, McHugh PF.

Q J Nucl Med Mol Imaging. 2011 Jun;55(3):250-64. Review.

17.

[Molecular imaging of cerebral blood flow and metabolism with SPET and PET in principal dementias].

Gerasimou G, Bostantjopoulou S, Gotzamani-Psarrakou A.

Hell J Nucl Med. 2009 Jan-Apr;12(1):79-83. Review. Greek, Modern.

PMID:
19330195
18.

Brain FDG PET and the diagnosis of dementia.

Shivamurthy VK, Tahari AK, Marcus C, Subramaniam RM.

AJR Am J Roentgenol. 2015 Jan;204(1):W76-85. doi: 10.2214/AJR.13.12363. Review.

PMID:
25539279
19.

Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease.

Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA.

Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S29-36. doi: 10.1016/j.jalz.2007.10.004. Epub 2007 Dec 21. Review.

PMID:
18631997
20.

Statistical Voxel-Based Methods and [18F]FDG PET Brain Imaging: Frontiers for the Diagnosis of AD.

Gallivanone F, Della Rosa PA, Castiglioni I.

Curr Alzheimer Res. 2016;13(6):682-94. Review.

PMID:
26567733

Supplemental Content

Support Center